Switching From MEDVi to PlexusDx: Price and Transfer Process

Last reviewed: September 7, 2026 Last updated: September 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

MEDVi's advertised first-month rates for compounded semaglutide injection and tirzepatide jump to higher refill prices after the introductory period, adding $1,200 per year compared with PlexusDx's month-to-month pricing on the same compounds. Both programs include medication, clinician visits, and shipping in one price; neither charges a membership fee for compounded pathways. The transfer itself is straightforward: complete a new intake, have a licensed provider review your current regimen and dose, and coordinate timing so your next shipment arrives before your MEDVi supply ends. No universal guarantee covers dose continuity or eligibility—each provider evaluates independently—but most patients established on maintenance doses transition without interruption when clinical records are current.

At-a-glance comparison

Sources: MEDVi pricing and service details captured September 4, 2026; PlexusDx pricing verified July 20 and September 7, 2026; review ratings captured September 4, 2026.

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Ongoing cost comparison: first month versus refill

MEDVi's checkout flow displays a first-month introductory rate and a separate refill rate. For compounded semaglutide injection, the introductory price is $179 (first-month rate, captured September 4, 2026), and the refill rate—the price you pay every month afterward—is $299. For compounded tirzepatide injection, the introductory rate is $279 (first-month rate, captured September 4, 2026) and the refill rate is $399. Oral formulations carry a $70 surcharge: semaglutide tablets start at $249 (first month) and refill at $369; tirzepatide oral pricing follows the same $279 first-month and $399 refill structure as the injection. These figures were verified at checkout on September 4, 2026.

PlexusDx publishes a single ongoing rate for each commitment tier. Compounded semaglutide injection is $189 per month on the month-to-month plan, $169 per month on a three-month prepaid commitment, and $149 per month on a six-month prepaid commitment. Compounded tirzepatide injection is $289 month-to-month, $269 on the three-month plan, and $249 on the six-month plan. Oral semaglutide is $289 month-to-month; oral tirzepatide is $349 month-to-month. Every tier includes the medication, a provider visit, prescription review, and shipping; no separate membership fee applies to any compounded program.

12-month cost calculation: semaglutide injection

MEDVi (month-to-month billing, first-month introductory rate then refill rate):
Month 1: $179 (first-month introductory rate, captured September 4, 2026)
Months 2–12: $299 × 11 = $3,289
Total over 12 months: $3,468 (our calculation)

PlexusDx (month-to-month):
$189 × 12 = $2,268 (our calculation)

PlexusDx (three-month prepaid commitment, per-month equivalent):
$169 × 12 = $2,028 (our calculation; prepaid per-month equivalent)

PlexusDx (six-month prepaid commitment, per-month equivalent):
$149 × 12 = $1,788 (our calculation; prepaid per-month equivalent)

Difference: Switching from MEDVi's ongoing refill rate to PlexusDx month-to-month saves $1,200 over 12 months on semaglutide injection (our calculation: $3,468 − $2,268). The six-month PlexusDx plan saves $1,680 over the same period compared with MEDVi's refill rate.

12-month cost calculation: tirzepatide injection

MEDVi (month-to-month billing, first-month introductory rate then refill rate):
Month 1: $279 (first-month introductory rate, captured September 4, 2026)
Months 2–12: $399 × 11 = $4,389
Total over 12 months: $4,668 (our calculation)

PlexusDx (month-to-month):
$289 × 12 = $3,468 (our calculation)

PlexusDx (three-month prepaid commitment, per-month equivalent):
$269 × 12 = $3,228 (our calculation; prepaid per-month equivalent)

PlexusDx (six-month prepaid commitment, per-month equivalent):
$249 × 12 = $2,988 (our calculation; prepaid per-month equivalent)

Difference: Switching from MEDVi's ongoing tirzepatide refill rate to PlexusDx month-to-month saves $1,200 over 12 months (our calculation: $4,668 − $3,468). The six-month plan saves $1,680 annually.

Oral formulations

MEDVi's oral semaglutide (tablet) costs $249 the first month (introductory rate, captured September 4, 2026) and $369 per month at refill, totaling $4,308 over 12 months (our calculation: $249 + $369 × 11). PlexusDx oral semaglutide is $289 month-to-month, totaling $3,468 over 12 months—an $840 annual saving (our calculation). For tirzepatide oral, MEDVi's first-month rate is $279 (introductory rate, captured September 4, 2026) and refill is $399, matching the injection pricing; PlexusDx oral tirzepatide is $349 month-to-month.

The transfer process: what to expect

Switching compounded GLP-1 providers mid-program involves four practical steps: eligibility review, dose coordination, shipment timing, and record transfer. No provider guarantees that your current dose or medication will continue—each licensed clinician evaluates independently using their own protocols and formulary—but most established patients on maintenance doses transition without interruption when records are current and the clinical picture is stable.

Step 1: New intake and provider review

You complete a medical intake that covers your weight history, current medications, side effects, and goals. Disclose your current GLP-1 compound, dose, frequency, and how long you have been at that dose. A licensed provider at the new program reviews your intake, prior records if available, and determines whether continuing or adjusting your regimen is appropriate. This review is required—no telehealth provider may prescribe a controlled or compound medication without an individualized clinical evaluation.

Step 2: Dose and formulation coordination

If your current provider has you on 1 mg semaglutide weekly or 7.5 mg tirzepatide weekly, communicate that dose explicitly. The new provider may continue the same dose, adjust it based on your progress and tolerance, or recommend a different titration schedule. Differences in compounding pharmacy formulation, concentration, or delivery device sometimes require dose recalibration even when the active ingredient is identical. Your new provider will explain any changes and the clinical reasoning behind them.

Step 3: Shipment timing

Coordinate your first shipment from the new provider to arrive before your current supply ends. Most compounding pharmacies ship within two to five business days of prescription approval. If you have one week of medication remaining when you start a new intake, allow at least 7–10 days of buffer. Some patients overlap by one shipment—paying both providers for one cycle—to avoid a gap, then cancel the prior program once the new supply is confirmed.

Step 4: Canceling the prior program

MEDVi's month-to-month plan has no contract and can be canceled anytime; the company describes the process as a monthly refill form with cancel-anytime flexibility. If you prepaid a multi-month bundle with MEDVi, the company's policy states that unused months are non-refundable. Confirm your next charge date, cancel before that date, and request written confirmation of cancellation. Keep records of your final dose, shipment dates, and any side effects or dose adjustments for your new provider's file.

Service differences that matter during a transfer

Both MEDVi and PlexusDx operate asynchronous telehealth models: you complete an intake, a provider reviews it, and medication ships from a compounding pharmacy if approved. The included services differ slightly.

MEDVi includes unlimited support access, free care coaching, a free dietitian visit, and unlimited doctor calls in its advertised package. The program's Trustpilot profile shows 4.3 stars across approximately 15,000 reviews (captured September 2026), with recurring themes in negative reviews citing delayed responses, billing confusion around the introductory-versus-refill structure, and difficulty reaching support during dose-adjustment windows.

PlexusDx includes a free check-in with a Doctor of Pharmacy as part of the standard program and offers an optional DNA test add-on ($298 standalone, $99 for program members; the test does not select or predict a medication—your provider decides). The company holds a 4.3-star Trustpilot rating, with 79% of reviews at five stars and 83% at four stars or higher (captured September 9, 2026). Both programs include shipping and do not charge separately for dose increases.

When ongoing cost justifies a switch

The $1,200 annual difference on semaglutide and tirzepatide between MEDVi's refill rate and PlexusDx's month-to-month rate is largest for patients who have already used their MEDVi first-month discount and are paying the $299 or $399 refill price. If you are still in your first MEDVi month, the cost advantage appears in month two. The cumulative savings grow linearly: $100 per month on semaglutide, $110 per month on tirzepatide (comparing MEDVi refill rate to PlexusDx month-to-month).

Prepaid PlexusDx commitments widen the gap further—$149 per month for six-month semaglutide injection versus MEDVi's $299 refill is a $150 monthly difference—but prepayment carries risk if your dose needs to change, if you experience intolerable side effects, or if you decide to stop treatment. Month-to-month plans preserve flexibility while still capturing most of the cost advantage.

When staying with MEDVi makes sense

Switching providers mid-program introduces coordination overhead, a new clinical relationship, and the administrative work of transferring records and timing shipments. If you are currently tolerating your MEDVi regimen well, have responsive support contact, and value the included dietitian visit and care coaching that MEDVi advertises, the annual cost difference may not justify the disruption—especially if you are within a few months of your goal weight or planning to transition to maintenance dosing soon.

MEDVi offers 0% financing via Klarna on multi-month bundles, spreading payment over 12 months; the company states it is not a party to that financing agreement. If cash flow is a larger constraint than total cost, and you prefer the budget predictability of installment payment, MEDVi's financing option may outweigh PlexusDx's lower sticker price. Verify the financing terms, total amount financed, and any fees directly with the financing provider.

Patients who have already prepaid a MEDVi multi-month bundle face a sunk-cost decision: the company's policy describes those bundles as non-refundable for unused months. Switching before the prepaid period ends forfeits the remaining value. In that scenario, staying with MEDVi until the prepaid term concludes, then switching, avoids the double payment.

Choose PlexusDx if…

You want a transparent per-month price with no introductory-rate structure, you are currently paying MEDVi's $299 semaglutide or $399 tirzepatide refill rate, and the $100–$110 monthly savings justifies the effort of transferring records and coordinating shipment timing. PlexusDx's month-to-month flexibility suits patients who are mid-titration, uncertain about long-term adherence, or prefer the option to pause or switch formulations without prepayment penalties. The included pharmacist check-in supports patients who have questions about drug interactions, side-effect management, or dose timing that fall outside a physician's visit scope.

Methodology and freshness

We captured MEDVi's advertised first-month and refill pricing by advancing through the company's checkout flow on September 4, 2026, recording the figures displayed at the payment-method step for compounded semaglutide injection, semaglutide tablet, and tirzepatide. MEDVi's service inclusions, cancellation terms, and financing options were documented from the same checkout session and the company's FAQ. PlexusDx pricing was verified from internal records on July 20 and September 7, 2026. Review ratings for both programs were captured from Trustpilot on September 4, 2026.

All 12-month cost totals, per-month prepaid equivalents, and savings figures are our calculations, derived by multiplying published monthly rates by 12 or by summing MEDVi's first-month and 11-refill structure. We label every derived figure as "our calculation" in the text.

Neither provider's website publishes a guaranteed transfer protocol or dose-continuity policy. The transfer-process description reflects standard telehealth intake requirements and the practical steps reported by patients switching between compounded GLP-1 programs; no provider can guarantee eligibility, dose matching, or uninterrupted treatment.

Frequently Asked Questions

Will my dose stay the same if I switch from MEDVi to PlexusDx?

Not automatically. A licensed provider at PlexusDx reviews your current dose, how long you have been at that dose, your tolerance, and your progress, then decides whether to continue, adjust, or retitrate. Most patients on stable maintenance doses transition without interruption, but no provider guarantees dose continuity—each evaluation is independent.

Can I use my remaining MEDVi medication while I wait for my PlexusDx shipment?

Yes. Coordinate timing so your first PlexusDx shipment arrives before your MEDVi supply ends. Most compounding pharmacies ship within two to five business days of prescription approval; allow 7–10 days of buffer if you have one week of medication remaining when you start the new intake.

Does PlexusDx charge a membership fee like some other programs?

No. PlexusDx charges $0 membership fee. The per-month price covers medication, provider visit, prescription, and shipping. MEDVi also charges $0 membership for compounded pathways but charges $99 per month for its branded Wegovy and Zepbound pathway.

What happens to my MEDVi prepaid bundle if I switch mid-term?

MEDVi states that multi-month bundles are non-refundable for unused months. If you prepaid three or six months and switch before the term ends, you forfeit the remaining value. Confirm your bundle end date and any refund exceptions directly with MEDVi before canceling.

How do I cancel my MEDVi subscription after I switch?

MEDVi's month-to-month plan has no contract; the company describes it as a monthly refill form with cancel-anytime terms. Log in to your account, locate the cancellation or subscription-management section, cancel before your next charge date, and request written confirmation. Keep a record of your final shipment and dose for your new provider's file.

Sources

• MEDVi advertised pricing and service inclusions, captured via checkout flow September 4, 2026
• MEDVi FAQ and financing terms, accessed September 4, 2026
• PlexusDx pricing and program details, verified July 20 and September 7, 2026
• Trustpilot review data for MEDVi and PlexusDx, captured September 4, 2026
• 12-month cost calculations: our calculations based on published per-month rates

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.